ERGOLOID MESYLATES

Pre-Launch

ergoloid mesylates

ANDASUBLINGUALTABLET

Lifecycle

Pre-Launch

Data completeness

3/8 — Basic

ERGOLOID MESYLATES (ergoloid mesylates) by PharmaIN is clinical pharmacology there is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency. Approved for the treatment of acute, chronic psychosis, regardless of etiology (see ) and 2 more indications.

Drug data last refreshed 1mo ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY There is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.…

Indications (5)

Worked on ERGOLOID MESYLATES at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.